Physician profile
Joseph Carr
NPI 1043673742
$2,226.02
in general payments reported to CMS, 2019-2025
19 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $116 · 2021: $651 · 2022: $75.96 · 2023: $271 · 2024: $608 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $514 · Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $513.52 |
| Food and Beverage | $490.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $737.78 | 2019-2024 | Wavelight Refractive Suite, Eysuvis, Acrysof Iq Panoptix Uv Iol |
| Carl Zeiss Meditec USA, INC. | $551.19 | 2024 | Lumera 700 |
| Johnson & Johnson Surgical Vision, INC. | $253.38 | 2021-2025 | Tecnis Iol |
| Novo Nordisk INC | $108.99 | 2022-2023 | Novoseven |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $65.73 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $60.65 | 2021 | |
| Horizon Therapeutics Plc | $51.12 | 2023 | Tepezza |
| Allergan, INC. | $45.65 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $38.96 | 2022-2023 | Vyzulta |
| Sight Sciences, INC. | $34.47 | 2025 | Omni Surgical System |
| Glaukos Corporation | $31.71 | 2025 | Idosetr, Istent Infinite |
| New World Medical,INC. | $27.72 | 2021-2023 | |
| Aerie Pharmaceuticals, INC. | $26.51 | 2021 | |
| Amgen INC. | $23.64 | 2025 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $20.91 | 2024 | Tyrvaya |
| Dompe US, INC. | $19.95 | 2025 | Oxervate |
| Abbvie INC. | $14.04 | 2024 | |
| Sun Pharmaceutical Industries INC. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.